Lipin-1 as a novel therapy target of muscular dystrophy
OwnerHongmei Reninventor
Life of this patent
Estimating the term…
Abstract
Methods for treatment of Duchenne's muscular dystrophy and several clinically related conditions in subjects in need thereof are provided. In further aspects, methods are provided for decreasing muscle degeneration in a subject in need thereof. In even further aspects, methods of enhancing sarcolemma stability and or/integrity in muscle cells lacking functional dystrophin in a subject in need thereof are provided. In aspects, the above-methods comprise administering a therapeutically effective amount of a composition suitable for increasing expression of a LPIN1 gene or a lipin-1 protein levels in a muscle cell of said subject; and decreasing muscle degeneration and improving exercise endurance and muscle contractile force in said subject by said step of administering.
Claims23
A method of treating muscle weakness and wasting in a subject in need thereof, wherein the subject has Duchenne's muscular dystrophy (DMD), the method comprising administering to a muscle cell of the subject a therapeutically effective amount of a composition suitable for causing expression of a lipin-1 protein in the muscle cell of said subject, wherein the composition comprises an expression vector comprising a nucleotide encoding a lipin-1 protein.
Dependencies are inferred from the claim text.